Replies to post #184155 on Biotech Values

[mcbio]

Brad Loncar’s blog on FPRX (which you presumably concur with)

Absolutely. As a shareholder, I much prefer companies I'm invested in to sacrifice less short-term in cash to be involved with one of the leading companies in a given space rather than accepting more up-front to be paired with a second-tier player in a given space. BMY seems to be one of the key players in the immuno onc space. Besides, I view the $30M payment itself as very meaningful to FPRX.

[DewDiligence]

FPRX selling $86.3M* of stock on unspecified terms:

http://finance.yahoo.com/news/five-prime-announces-75-million-210100224.html

*Assuming exercise of underwriter’s option.